BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9815691)

  • 21. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
    Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
    Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
    Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
    Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
    Horita H; Frankel AE; Thorburn A
    Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
    [No Abstract]   [Full Text] [Related]  

  • 28. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
    Kreitman RJ; Pastan I
    Blood; 1997 Jul; 90(1):252-9. PubMed ID: 9207460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.
    Shao Y; Warman BE; Perentesis JP
    Methods Mol Biol; 2001; 166():31-53. PubMed ID: 11217375
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
    Frankel AE; Hall PD; Burbage C; Vesely J; Willingham M; Bhalla K; Kreitman RJ
    Blood; 1997 Nov; 90(9):3654-61. PubMed ID: 9345050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.
    Calvo KR; Sykes DB; Pasillas MP; Kamps MP
    Oncogene; 2002 Jun; 21(27):4247-56. PubMed ID: 12082612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
    Kim CN; Bhalla K; Kreitman RJ; Willingham MC; Hall P; Tagge EP; Jia T; Frankel AE
    Leuk Res; 1999 Jun; 23(6):527-38. PubMed ID: 10374846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective cytotoxicity of recombinant STXA1-GM-CSF protein in hematopoetic cancer cells.
    Roudkenar MH; Jafari A; Oloomi M; Bouzari S
    Cell Biol Toxicol; 2006 May; 22(3):213-9. PubMed ID: 16598407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
    Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
    Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF.
    Senchenkov A; Han TY; Wang H; Frankel AE; Kottke TJ; Kaufmann SH; Cabot MC
    Blood; 2001 Sep; 98(6):1927-34. PubMed ID: 11535531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
    Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
    Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms.
    Horita H; Frankel AE; Thorburn A
    PLoS One; 2008; 3(12):e3909. PubMed ID: 19079542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3.
    Kaplinsky C; Lotem J; Sachs L
    Leukemia; 1996 Mar; 10(3):460-5. PubMed ID: 8642862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.